This is the authors' abstract. We don't add key points for this paper.
Daily injections of anakinra markedly improved clinical and laboratory manifestations in patients with neonatal-onset multisystem inflammatory disease, with or without CIAS1 mutations. (ClinicalTrials.gov number, NCT00069329 [ClinicalTrials.gov].).
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Goldbach‐Mansky et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: